Anne M. Traynor, MD
Dr. Anne M. Traynor is a hematologist, medical oncologist, and palliative care physician at University of Wisconsin Health and the Carbone Comprehensive Cancer Center in Madison, Wisconsin. She specializes in the treatment of patients with lung cancer. She is also a faculty member within the Department of Medicine and faculty director of the University of Wisconsin Carbone Cancer Center’s Clinical Research Central Office.[1]
Dr. Traynor feels fortunate to work with a competent and compassionate multidisciplinary treatment team dedicated to improving patient outcomes. She is dedicated to minimizing side effects and working to make treatment decisions with her patients based on their concerns, their plans, their fears, and their goals, as well as her medical knowledge.[1]
Dr. Traynor is actively involved on several committees dedicated to oncology research, including the Big Ten Cancer Research Consortium, the National Comprehensive Cancer Network Oncology Research Program, and the Eastern Cooperative Oncology Group.[1]
Research
In addition to her clinical care of patients, Dr. Traynor is the Faculty Director of the University of Wisconsin Comprehensive Cancer Center (UWCCC) Clinical Research Central Office. In that role, she supports both patients and investigators as they work together to develop better anti-cancer medications. Before assuming the role of Faculty Director of UWCCC, she led the Wisconsin Oncology Network, a cancer research group dedicated to conducting clinical trials throughout the state. She also chaired the UWCCC Lung Cancer Research Group and several clinical research committees. She has represented the UWCCC in meetings with several national oncology research organizations.[1]
Dr. Traynor’s recent publications include:[1]
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial. Michael F Bassetti, Brett A Morris, Nan Sethakorn, Joshua M Lang, Jennifer L Schehr, Shuang George Zhao, Zachary S Morris, Darya Buehler, Jens C Eickhoff, Paul M Harari, Anne M Traynor, Toby C Campbell, Andrew M Baschnagel, Ticiana A Leal
MRTX-500 Phase 2 Trial: Sitravatinib with Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony Pham, Robert Jotte, David S Hong, Edward B Garon, Anne Traynor, Peter Olson, Lisa Latven, Xiaohong Yan, Ronald Shazer, Ticiana A Leal
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. Tareq Salous, Nikhil A Shukla, Sandra K Althouse, Susan M Perkins, Muhammad Furqan, Ticiana Leal, Anne M Traynor, Lawrence E Feldman, Nasser H Hanna, Greg A Durm
